Standard and Emerging Therapies for Metastatic Differentiated Thyroid Cancer
Open Access
- 1 February 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 15 (2) , 146-156
Abstract
Learning Objectives: After completing this course, the reader will be able to: Describe the role and limitations of traditional treatments for metastatic differentiated thyroid cancer.Discuss the molecular basis of and clinical evidence for novel and emerging treatments for metastatic differentiated thyroid cancer.Identify suitable candidates for clinical trials among your patients with radioactive iodine refractory, metastatic differentiated thyroid cancer and enroll them. This article is available for continuing medical education credit at CME.TheOncologist.com Differentiated thyroid cancer accounts for >90% of cases of thyroid cancer, with most patients having an excellent prognosis. Distant metastases occur in 10%–15% of patients, decreasing the overall 10-year survival rate in this group to 40%. Radioactive iodine has been the mainstay of treatment for distant metastases, with good results when lesions retain the ability to take up iodine. For patients with metastatic disease resistant to radioactive iodine, treatment options are few and survival is poor. Chemotherapy and external beam radiotherapy have been used in these patients, but with disappointing results. In recent years, our understanding of the molecular pathways involved in thyroid cancer has increased and a number of molecular targets have been identified. These targets include the proto-oncogenes BRAF and RET, known to be common mutations in thyroid cancer; vascular endothelial growth factor receptor and platelet-derived growth factor receptor, associated with angiogenesis; and the sodium-iodide symporter, with the aim of restoring its expression and hence radioactive iodine uptake. There are now multiple trials of tyrosine kinase inhibitors, angiogenesis inhibitors, and other novel agents available to patients with metastatic thyroid cancer. This review discusses both traditional and novel treatments for metastatic differentiated thyroid cancer with a particular focus on emerging treatments for patients with radioactive iodine–refractory disease.Keywords
Funding Information
- New South Wales Cancer Institute
This publication has 126 references indexed in Scilit:
- Thoracic metastasectomy for thyroid malignancies☆☆☆European Journal of Cardio-Thoracic Surgery, 2009
- Recent Advances in Molecular Biology of Thyroid Cancer and Their Clinical ImplicationsOtolaryngologic Clinics of North America, 2008
- Molecular pathology of thyroid cancer: diagnostic and clinical implicationsBest Practice & Research Clinical Endocrinology & Metabolism, 2008
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- Patterns of relapse following radiotherapy for differentiated thyroid cancer: Implication for target volume delineationRadiotherapy and Oncology, 2008
- Potent Inhibition of Thyroid Cancer Cells by the MEK Inhibitor PD0325901 and Its Potentiation by Suppression of the PI3K and NF-κB PathwaysThyroid®, 2008
- New therapeutic approaches for metastatic thyroid carcinomaThe Lancet Oncology, 2007
- Increasing Incidence of Thyroid Cancer in the United States, 1973-2002JAMA, 2006
- Clinical profile of long-term survivors of breast or thyroid cancer with metastatic spinal tumoursInternational Orthopaedics, 2006
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000